TruScreen Limited (NZX:TRU) (TruScreen or the “Company”) is pleased to advise that it has received approval from the Ministry of Health (MOH) of the Vietnam Government for the commercial roll out of the TruScreen cervical cancer screening device.
This landmark approval is granted initially for the Hanoi Obstetrics and Gynaecology Hospital (HOGH). It is anticipated that further rollouts across other public and private hospitals in Vietnam will occur this year.
The approval follows a MOH managed clinical trial covering 989 patients which was concluded successfully with a positive clinical outcome at the HOGH. The trial compared the specificity and sensitivity between the results from the TruScreen hand held real time screening device and Pap test for the detection of cervical early stage pre-cancerous, and progressing intraepithelial lesions. The outcome of the trial was assessed by the Vietnam Ministry of Health Professional Advisory Committee which endorsed and approved the introduction of TruScreen cervical cancer screening technology in Vietnam.
TruScreen CEO, Victoria Potarina comments, “The Vietnam government approval of TruScreen is a significant milestone for the Company. Together with our local distributor, Gorton Health Services we have been engaged on this project for over two years, in a review process that has been extremely thorough.
We look forward to working with HOGH and the MOH in improving the health and lives of women in Vietnam.”
This announcement has been approved by the Board.